Beta Blockers In Acute Ischemic Stroke

• Status: Completed
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this trial is to assess the safety and efficacy of neuro- and cardioprotective effects of propranolol in acute ischemic stroke. Furthermore, exploratory analyses of cardiologic-electrophysiologic and immunologic parameters will be performed.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wilhelm Haverkamp
• Collaborator: German Federal Ministry of Education and Research
• Treatments: Adrenergic beta-Antagonists; Propranolol

Criteria

Inclusion Criteria:

• Symptom onset within 18 hours

• Acute ischemic MCA-territory stroke

• Patients with suspected stroke in MCA-territory and a) NIHSS > 3 or b) imaging evidence of MCA-infarction

Exclusion Criteria:

• Patients already receiving beta-blockers

• Anti-arrhythmic, antiinfectious, antiinflammatory or immunosuppressive therapy

• Patients with a major heart disease, hypotension, bradycardia or any contraindication to the use of Propranolol